Chemistry Wealth Management LLC Has $3.18 Million Position in UnitedHealth Group Incorporated $UNH

Key Points

• Chemistry Wealth Management LLC increased its stake in UnitedHealth Group by 24%, owning a total of 10,177 shares valued at approximately $3.18 million.
• UnitedHealth Group reported earnings per share of $4.08 for the last quarter, which fell short of analysts' expectations of $4.45.
• The company announced a quarterly dividend of $2.21 per share, equating to an annualized dividend of $8.84 and a yield of 2.5%.

Chemistry Wealth Management LLC boosted its holdings in UnitedHealth Group Incorporated (NYSE:UNH - Free Report) by 24.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,177 shares of the healthcare conglomerate's stock after purchasing an additional 1,970 shares during the quarter. UnitedHealth Group comprises approximately 0.7% of Chemistry Wealth Management LLC's investment portfolio, making the stock its 24th largest holding. Chemistry Wealth Management LLC's holdings in UnitedHealth Group were worth $3,175,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bayforest Capital Ltd boosted its holdings in shares of UnitedHealth Group by 685.7% in the 1st quarter. Bayforest Capital Ltd now owns 55 shares of the healthcare conglomerate's stock worth $29,000 after buying an additional 48 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd raised its stake in UnitedHealth Group by 416.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 62 shares of the healthcare conglomerate's stock valued at $32,000 after acquiring an additional 50 shares during the period. Copia Wealth Management bought a new stake in UnitedHealth Group in the 4th quarter valued at about $42,000. IAG Wealth Partners LLC bought a new stake in UnitedHealth Group in the 1st quarter valued at about $42,000. Finally, Investment Management Corp VA ADV bought a new stake in UnitedHealth Group in the 4th quarter valued at about $44,000. 87.86% of the stock is owned by hedge funds and other institutional investors.

UnitedHealth Group Stock Performance

NYSE:UNH opened at $352.61 on Monday. The firm has a market cap of $319.35 billion, a PE ratio of 15.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.45. UnitedHealth Group Incorporated has a fifty-two week low of $234.60 and a fifty-two week high of $630.73. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.85 and a current ratio of 0.85. The business has a 50 day moving average price of $291.98 and a 200-day moving average price of $368.31.

UnitedHealth Group (NYSE:UNH - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The healthcare conglomerate reported $4.08 earnings per share for the quarter, missing analysts' consensus estimates of $4.45 by ($0.37). UnitedHealth Group had a net margin of 5.04% and a return on equity of 23.32%. The company had revenue of $111.62 billion for the quarter, compared to analysts' expectations of $111.75 billion. During the same period last year, the company posted $6.80 EPS. The business's revenue for the quarter was up 12.9% compared to the same quarter last year. UnitedHealth Group has set its FY 2025 guidance at 16.000- EPS. Equities research analysts predict that UnitedHealth Group Incorporated will post 29.54 earnings per share for the current year.

UnitedHealth Group Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 23rd. Shareholders of record on Monday, September 15th will be given a dividend of $2.21 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $8.84 annualized dividend and a yield of 2.5%. UnitedHealth Group's dividend payout ratio (DPR) is currently 38.30%.

Analysts Set New Price Targets

UNH has been the topic of a number of research reports. KeyCorp lowered their price objective on UnitedHealth Group from $400.00 to $350.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 30th. JPMorgan Chase & Co. decreased their price target on UnitedHealth Group from $418.00 to $310.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 6th. UBS Group reiterated a "buy" rating on shares of UnitedHealth Group in a research report on Thursday, July 17th. Morgan Stanley upped their price target on UnitedHealth Group from $325.00 to $395.00 and gave the company an "overweight" rating in a research report on Friday. Finally, Wall Street Zen cut UnitedHealth Group from a "buy" rating to a "hold" rating in a research report on Saturday, May 24th. Sixteen investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, UnitedHealth Group presently has an average rating of "Moderate Buy" and an average target price of $358.95.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.